Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASOX in advanced pancreatic adenocarcinoma
NCT04662112Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by Asan Medical Center. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Objective Response Rate at 6 months. Started Jun 2021; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04662112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662112.